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Abstract
Background: Numerous papers have addressed the association of mutations and polymorphisms of
susceptibility genes with autoimmune inflammatory disorders. We investigated whether polymorphisms
that confer susceptibility to Crohn's disease could be classified also as predisposing factors for the
development of primary sclerosing cholangitis and primary biliary cirrhosis in Polish patients.
Methods: The study included 60 patients with CD, 77 patients with PSC, of which 61 exhibited IBD (40
UC, 8 CD, and 13 indeterminate colitis), and 144 patients with PBC. All the patients were screened against
Crohn's disease associating genetic polymorphisms.
The polymorphisms were chosen according to previously confirmed evidence for association with Crohn's
disease, including Pro268Ser, Arg702Trp, Gly908Arg and 1007fs in NOD2/CARD15, Leu503Phe/-207G>C
in SLC22A4/OCTN1/SLC22A5/OCTN2, Arg30Gln in DLG5, Thr300Ala in ATG16L1, and Arg381Gln, His3Gln
and exon-3'UTR in IL23R. Genotyping was carried out using TaqMan SNP genotyping assays.
Results: We confirmed a strong association between three NOD2/CARD15 gene variants (Pro268Ser, OR
= 2.52, 95% CI = 1.34 – 4.75); (Arg702Trp, OR = 6.65, 95% CI = 1.99 – 22.17); (1007fs, OR = 9.59, 95%
CI = 3.94 – 23.29), and a weak association between both the protective OCTN1/OCTN2 CC haplotype (OR
= 0.28, 95% CI = 0.08 – 0.94), and a variant of ATG16L1 gene (Thr300Ala, OR = 0.468, 95% CI = 0.24 –
0.90) with Crohn's disease. In contrast, none of the polymorphisms exhibited association with
susceptibility to primary sclerosing cholangitis and primary biliary cirrhosis, including a group of primary
sclerosing cholangitis patients with concurrent IBD.
Conclusion:  Although the clinical data indicate non-random co-occurrence of inflammatory bowel
disease and primary sclerosing cholangitis, consistently with the previously published studies, no genetic
association was found between the genetic variants predisposing to Crohn's disease and hepatobiliary
autoimmune disorders. However, since estimation of genetic variant disproportion is limited by sample
size, these negative results may also indicate that eventually shared genetic predispositions are too little
to be captured by small patient groups.
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Background
Identification of the mechanisms of autoimmune inflam-
matory disease development in the gastrointestinal tract is
an emerging topic of research. Inflammatory bowel dis-
ease (IBD) is thought to result from immune-mediated
tissue injury, primed by the enteric microflora, in geneti-
cally predisposed subjects. IBD phenotypically occurs in
the form of Crohn's disease (CD) or ulcerative colitis
(UC). In these disorders, chronic mucosal inflammation
results from inappropriate and overreactive mucosal
response to intestinal bacteria followed by activation of
inflammatory cells and production of inflammatory
mediators [1]. Primary sclerosing cholangitis (PSC) is a
chronic inflammatory disease of the hepatic bile ducts
that likely develops as a result of an inappropriate
immune mediated process [2]. Nearly 80% of northern
European PSC patients also have concomitant IBD,
mostly in the form of UC [3]. Primary biliary cirrhosis
(PBC) is another autoimmune chronic cholestatic liver
disorder that may also develop as a result of an abnormal
immune response to stimulating environmental or infec-
tious agents [4].
As in other autoimmune diseases, the specific alleles of
the human leukocyte antigen (HLA) complex represent
genes associated with susceptibility to PSC [5-7], PBC
[8,9] and IBD [10]. It has been reported that the genetic
predisposition to CD is caused by alterations in several
genes, including NOD2/CARD15, OCTN1, OCTN2, DLG,
ATG16L1  and  IL23R  [11-14]. Several other non-HLA
genes are also involved in PCS and PBC disease suscepti-
bility [7,15].
According to our current understanding of CD, PSC and
PBC are complex diseases in which the genetic determi-
nants contributing to disease susceptibility interact with
environmental factors. However, the mechanisms under-
lying these interactions remain unclear. Considering high
frequency at which IBD and PSC are diagnosed together
[3], close spatial proximity of affected organs, and the fact
that common immune mediated processes are likely
involved in development of these diseases [16], searching
for common risk alleles for IBD and autoimmune choles-
tatic liver disorders seems to be relevant
Most of the susceptibility genes are considered to not be
directly involved in disease pathogenesis, but rather act as
environmental response modifiers. Given their subtle
individual impact on disease susceptibility, independ-
ently they may have little to no effect on disease progres-
sion and likely act in collaboration with other factors to
promote disease development. Moreover, disease genetic
markers vary among the populations studied, despite the
phenotypic similarity of disease. Thus, analyzing the
genetic background of disease is an important challenge,
and several studies have been performed with the purpose
of finding similarities in the molecular mechanism of
development of different inflammatory disorders of the
alimentary tract. The aim of this study was to investigate
whether polymorphisms of CD susceptibility genes are
predisposing factors to the development of PSC and PBC
in a group of Polish patients.
Methods
Patients
The study included 60 patients with CD (28 men, range of
22 – 78 years old; median 39), 77 patients with PSC (45
men, range of 20 – 68 years old; median 33), of which 61
exhibited IBD as confirmed by endoscopy and histology
(40 UC, 8 CD, and 13 indeterminate colitis), and 144
patients with PBC (8 men, range of 40 – 72 years old;
median 58). All patients were diagnosed at the Depart-
ment of Gastroenterology and Hepatology, Medical
Center for Postgraduate Education and Cancer Center,
Warsaw, Poland. Diagnosis of CD was based on generally
accepted clinical, endoscopical and histological criteria.
The diagnosis of PSC was based on characteristic bio-
chemical and radiological features (irregularity of the int-
rahepatic and extrahepatic bile ducts in endoscopic
retrograde or magnetic resonance cholangiopancreatogra-
phy). PBC was diagnosed based on generally accepted
clinical, biochemical, serological (antimitochondrial anti-
body positivity by indirect immunofluorescence) and his-
tological findings [17].
The control group consisted of 139 healthy volunteers (74
men, range of 21 – 66 years old, median 32) recruited
from hospital staff, medical students, and healthy subjects
selected for screening colonoscopy. All patients and con-
trols were Polish Caucasians. The study was approved by
the local ethics committee (Medical Center for Postgradu-
ate Education and Cancer Center, Warsaw, Poland), and
all the participants provided appropriate consent. The
study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki.
Genotyping
Genomic DNA was extracted from whole blood treated
with EDTA using the NucleoSpin Blood Quick Pure kit
(Macherey-Nagel, Germany), following the manufac-
turer's protocol.
The selected polymorphisms of genes with previously
confirmed evidence for association with CD were as fol-
lows:  NOD2/CARD15: rs2066842 (Pro268Ser),
rs2066844 (Arg702Trp), rs2066845 (Gly908Arg),
rs5743293 (1007fs); in the SLC22A4/OCTN1/SLC22A5/
OCTN2  genes: rs1050152 (Leu503Phe)/rs2631367 (-
207G>C); in the DLG5 gene: rs1248696 (Arg30Gln); in
the ATG16L1 gene: rs2241880 (Thr300Ala); and in theBMC Medical Genetics 2008, 9:81 http://www.biomedcentral.com/1471-2350/9/81
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IL23R  gene: rs11209026 (Arg381Gln), rs1884444
(His3Gln), rs10889677 (exon-3'UTR).
Genotyping was carried out using TaqMan SNP Genotyp-
ing Assays (Applied Biosystems; Foster City, CA). The PCR
reactions were performed in 96-well plates on the ABI
PRISM 7000 Sequence Detection System (SDS) (Applied
Biosystems; Foster City, CA). Each well contained 20 ng
genomic DNA, 1.25 μL TaqMan SNP Genotyping Assay
(probes and primers mix), 12.5 μL TaqMan Universal PCR
Master Mix, No AmpErase UNG (Applied Biosystems; Fos-
ter City, CA), and 9.25 μL water. Two non-template-con-
trol wells were included on each plate. After DNA
amplification (95°C for 10 min, followed by 40 cycles of
92°C for 15 sec and 60°C for 1 min), fluorescence was
acquired and analyzed for allelic discrimination using the
ABI Prism 7000 SDS Software.
Statistical analyses
The frequency distribution of alleles, genotypes, and hap-
lotypes was compared using standard or Yates corrected χ2
test and Fisher's exact test when appropriate. Statistical
significance threshold level was Bonferroni corrected for
multiple hypothesis testing, according to the number of
genes tested. The p-value significance threshold level was
defined as 0.008. For the Fisher's exact tests, the STATIS-
TICA software was used. ORs with 95% confidence inter-
vals (95% CI) were calculated using a calculator available
at http://www.hutchon.net/ConfidOR.htm. LD analysis
and calculation of the Hardy-Weinberg equilibrium were
performed using the Haploview v3.2 software, available at
http://www.broad.mit.edu/mpg/haploview/. Statistical
power analyses were done using G*power's (ver. 3.0.10)
[18] post-hoc procedure for the Fisher's exact test.
Results and Discussion
Allelic distributions for all polymorphisms studied in the
patient and control groups are shown in Table 1, while
genotype counts for each of the studied groups are pre-
sented in Additional file 1 [see Additional file 1]. In the
control group, the genotype distributions for all polymor-
phisms were in Hardy-Weinberg equilibrium (p > 0.05).
Table 1: Allelic distribution in patients and healthy controls for all polymorphisms
Polymorphism Genotype CD PSC PBC Controls
NOD2/CARD15 Pro268Ser C/C 0.33 0.48 0.58 0.56
C/T 0.40 0.45 0.36 0,41
T/T 0.27 0.06 0.06 0.03
NOD2/CARD15 Arg702Trp C/C 0.83 0.92 0.93 0.97
C/T 0.17 0.08 0.07 0.03
T/T 0.00 0.00 0.00 0.00
NOD2/CARD15 Gly908Arg G/G 0.95 0.96 0.97 0.94
G/C 0.05 0.04 0.03 0.06
C/C 0.00 0.00 0.00 0.00
NOD2/CARD15 1007fs -/- 0.63 0.91 0.92 0.94
-/C 0.27 0.08 0.08 0.06
C/C 0.10 0.01 0.00 0.00
OCTN1 Leu503Phe C/C 0.27 0.35 0.37 0.37
C/T 0.50 0.52 0.43 0.46
T/T 0.23 0.13 0.20 0.17
OCTN2-207G>C G/G 0.25 0.28 0.30 0.27
G/C 0.47 0.54 0.43 0.46
C/C 0.27 0.18 0.27 0.27
DLG5 Arg30Gln C/C 0.80 0.77 0.82 0.80
C/T 0.18 0.21 0.17 0.19
T/T 0.02 0.03 0.01 0.01
IL23R Arg381Gln G/G 0.97 0.90 0.92 0.95
G/A 0.03 0.09 0.08 0.05
A/A 0.00 0.01 0.00 0.00
IL23R His3Gln C/C 0.19 0.26 0.23 0.30
C/A 0.59 0.57 0.54 0.49
A/A 0,22 0.17 0.23 0.22
IL23R exon-3'UTR C/C 0.40 0.53 0.51 0.49
C/A 0.52 0.41 0.40 0.42
A/A 0.08 0.07 0.08 0.09
ATG16L1 Thr300Ala C/C 0.39 0.29 0.25 0.23
C/T 0.42 0.51 0.52 0.50
T/T 0.19 0.20 0.23 0.27BMC Medical Genetics 2008, 9:81 http://www.biomedcentral.com/1471-2350/9/81
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The  Caspase Recruitment Activation Domain 15 (NOD2/
CARD15) gene is located in the proximal region of chro-
mosome 16 (16q12) and encodes the nucleotide-binding
oligomerization domain protein 2 (NOD2), which is a
cytosolic receptor for a bacterial peptidoglycan response
pathway [19]. Mutations in NOD2 result in immune sys-
tem dysfunctions [11,20] and are considered causative
genetic factors in the development of CD. NOD2/CARD15
mutations are also associated with susceptibility to other
granulomatous inflammatory disorders, such as early-
onset sarcoidosis and Blau syndrome [21,22].
Three of the four NOD2/CARD15  variants tested
(rs2066842, rs2066844, rs5743293) were strongly associ-
ated with CD (Table 2). In particular, a strong association
was observed with Pro268Ser and 1007fs SNPs with odds
ratio (OR) values over 10. Increased values of OR for
homozygous risk genotypes confirm previously described
codominance of these variants. The observed allele distri-
bution was similar to those reported in other Caucasian
CD patient groups [23-25].
The autophagy-related 16-like 1 (ATG16L1) gene encodes
the protein component of the autophagosome pathway of
intracellular bacteria processing. The T300A variant
(rs2241880) was previously considered to be a risk factor
for CD development [26,27]. In our CD patients, how-
ever, this variant demonstrated only a weak associaf2tion
with CD, as the p-value (= 0.022) did not pass the Bonfer-
roni corrected significance threshold level of 0.008.
The organic cation transporters from the family of solute
carrier protein (SLC22A4/OCTN1 and SLC22A5/OCTN2)
genes are located on chromosome 5 (5q31) within the
IBD5 region [28]. The 1672C/T (Leu503Phe) missense
variant of SLC22A4/OCTN1  (rs1050152) potentially
alters the carnitine adsorption and the exchange of other
positively charged compounds between the cell and extra-
cellular matrix [29]. Also included in this study is the G-
to-C transversion in the SLC22A5/OCTN2  promoter
(rs2631367), which is thought to affect a heat shock tran-
scription factor binding element [30]. The variants of both
genes were previously found in linkage disequilibrium,
enabling the selection of a two-allele CD risk haplotype
[28,31]. This finding, however, has not been confirmed by
other studies [29].
As shown in Table 3, there was a weak association
between the protective OCTN1/OCTN2 CC haplotype and
CD (OR = 0.28; CI = 0.08 – 0.94; p = 0.0298). A strong
linkage disequilibrium was found between the NOD2/
CARD15 Pro268Ser loci and three other studied loci of
NOD2/CARD15. Analyses of reconstructed haplotypes for
each patient group showed that the odds of TC haplotype
of Pro268Ser and 1007fs loci is approximately ten times
higher (OR = 10.26; CI = 4.52 – 23.29; p =
0.0000000000671) among patients with CD compared to
healthy controls.
The  interleukine-23 receptor (IL23R) gene is located on
chromosome region 1p31, and encodes a subunit of the
IL23 receptor. IL23 and IL6 activate the STAT3 transcrip-
tion factor which in turn leads to differentiation of CD4+
helper T cells into Th17 cells that function in driving
autoimmune inflammation by producing pro-inflamma-
tory cytokines, such as IL-17A, IL-17F and IL-22 [13,32-
35]. Genetic variants of IL23R were identified as disease-
associated factors in chronic inflammatory disorders, such
as IBD [12], psoriasis, T-cell-mediated inflammatory dis-
ease of the skin [36], and ankylosing spondylitis [37],
indicating the involvement of the IL23/IL23R pathway in
the etiology of various autoimmune-related disorders.
Several genetic non-coding variants of this gene demon-
strated independent risk association with CD, while the
rare variant in the coding region of IL23R  (1142G/A;
Arg381Gln; rs11209026) has been regarded as a CD pro-
tective variant [12,13].
We did not find any association of CD not only with
Arg381Gln, but also two other more frequent variants of
IL23R. The frequency of the G/A genotype of rs11209026
SNP was 3.3% in CD (2 of 60) compared to 5.8% (8 of
139) in controls, and only one of the patients and con-
trols was homozygous for the AA genotype (not signifi-
Table 2: Statistical analyses for significant genotype associations
Patient group SNP Genotype OR 95% CI p-value Stat.
Power
Crohn's
disease
NOD2/CARD15 Pro268Ser C/T+T/T 
T/T
2.52 
12.18
1.34 – 4.75 
3.86 – 38.37
0.005 
0.0000003
0.59 
0.98
NOD2/CARD15 Arg702Trp C/T+T/T 
T/T
6.65 
n/a
1.99 – 22.17
n/a
0.0013 
n/a
0.71 
n/a
NOD2/CARD15 1007fs -/C+C/C 
C/C
9.59
>16
3.94 – 23.29
---
0.00000002 
0.0006
0.99
0.86
ATG16L1 Thr300Ala T/C+T/T 
T/T
0.468 
0.632
0.24 – 0.90 
0.30 – 1.34
0.022 
0.231
0.32 
0.05BMC Medical Genetics 2008, 9:81 http://www.biomedcentral.com/1471-2350/9/81
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cant). Thus, although this rare variant was found at a
similar proportion to that described from the genome-
wide scan-based population studies (2.5–3.0% versus 6.2–
6.8%; [13,38]), our small group of CD patients (N = 60)
was insufficient to reach statistical significance for this dis-
proportion.
The  Drosophila  disc large homolog 5 (DLG5) gene,
mapped to chromosome 10 (10q23), is a member of the
membrane-associated guanylate kinase gene family
[10,39] and encodes a protein involved in maintaining
the correct shape, polarity and growth of cells. The func-
tional variant (113G/A, Arg30Gln, rs1248696) has been
proposed to potentially lead to serious abnormalities in
both the structure and function of cells. Although the first
study of Stoll et al. [40] reported an association between
genetic variants in DLG5 and IBD, the more recent meta-
analysis of published data on Arg30Gln question this
association [10]. Our study did not show any association
between the Arg30Gln variant of DLG5 and CD.
In contrast to CD patients, none of the polymorphisms
showed association with PSC and PBC, two disorders of
autoimmune etiology. Furthermore, no significant associ-
ations were detected in PSC patients with concurrent IBD.
These negative results are consistent with the recently pub-
lished studies in Scandinavian PSC patients, the largest
PSC population in which genotyping has been performed
[2], and in a group of Hungarian and Polish patients with
PBC [41].
The present study confirms a strong association of NOD2/
CARD15 gene variants, and to a lesser extent the coding
ATG16L1 variant and the OCTN1/OCTN2 haplotype, with
CD in a relatively small Polish Caucasian patient group.
There was no evidence for significant association between
variants of IL23R  or DLG5  and CD. However, because
small sample size significantly limits estimation of genetic
variant disproportion, especially with a low prevalence of
allelic frequency, whether the result represents a true neg-
ative association or a false negative finding is somewhat
disputable, mainly due to insufficient power of statistical
tests [7]. In fact, calculation of the statistical testing power
reached decent values only for the three main NOD2/
CARD15 variants (Table 4). Therefore, considering SNP
frequencies, small patient groups and measured effect
size, our studies might not be able to confirm existing
weak and even moderate disease associations.
Conclusion
Although inappropriate immune mediated processes are
also related with PSC and PBC, this study and previously
published [2,41] studies have not identified common
allelic variants. In IBD, risk variants of genes encoding
proteins that are involved in signalling pathways activated
by bacterial products have been described. Consequently,
IBD is thought to result from dysfunction of the mucosal
immune response triggered by intestinal bacteria, and
defects in the early immune response may play a role in
the pathogenesis of CD [1,42,43]. However, this hypoth-
esis is based on statistical considerations rather than func-
Table 3: Statistical analyses using Haploview software (ver. 3.2) for significant haplotype associations.
Patient group SNP Haplotype OR 95% CI p-value
Crohn's disease NOD2/CARD15 Pro268Ser/Arg702Trp TC 2.25 1.41 – 3.58 0.0005
NOD2/CARD15 Pro268Ser/Gly908Arg TG 3.01 1.89 – 4.78 0.000002
NOD2/CARD15 Pro268Ser/1007fs TC 10.26 4.52 – 23.29 0.0000000000671
OCTN1/OCTN2 CC 0.28 0.08 – 0.94 0.0298
Table 4: Power of genotype association statistics given as 1-β 
error probability. The β represents the probability of falsely 
accepting H0 hypothesis (lack of association) when in fact H1 
hypothesis (association) is true.
Polymorphism Genet. model CD PSC PBC
NOD2/CARD15 Pro268Ser dominant 0.59 0.04 <0.01
recessive 0.98 0.03 0.04
NOD2/CARD15 Arg702Trp dominant 0.71 0.11 0.08
recessive n/a <0.01 n/a
NOD2/CARD15 Gly908Arg dominant <0.01 <0.01 0.05
recessive n/a n/a n/a
NOD2/CARD15 1007fs dominant 0.99 0.02 0.01
recessive 0.86 <0.01 n/a
OCTN1 Leu503Phe dominant 0.08 <0.01 <0.01
recessive 0.04 0.02 0.02
OCTN2-207G>C dominant <0.01 <0.01 0.01
recessive <0.01 0.09 <0.01
DLG5 Arg30Gln dominant <0.01 0.02 0.01
recessive <0.01 0.02 <0.01
IL23R Arg381Gln dominant <0.01 0.08 0.03
recessive <0.01 <0.01 n/a
IL23R His3Gln dominant 0.09 0.01 0.06
recessive <0.01 0.02 <0.01
IL23R exon-3'UTR dominant 0.05 0.01 0.01
recessive <0.01 0.01 <0.01
ATG16L1 Thr300Ala dominant 0.32 0.04 0.01
recessive 0.05 0.04 0.02BMC Medical Genetics 2008, 9:81 http://www.biomedcentral.com/1471-2350/9/81
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tional studies. It is noteworthy that only some CD patients
carry mutated NOD2/CARD15 and/or other risk gene var-
iants, and therefore, mechanisms for CD development
likely are not simply related to mutations within
described risk genes. Furthermore, the genetic background
of CD possibly is based on more causative genetic factors
than studied thus far, and each of them independently
may have a relatively weak impact on disease develop-
ment.
Such high complexity of disease background requires
mapping of genetic predisposition using genome-wide
and large-scale studies in well-defined populations.
Despite the fact that these kind of studies are still relatively
expensive, they are likely the most cost effective giving real
capacity to provide comprehensive insight into disease
development mechanisms.
Even though familial aggregation is observed in many
complex diseases, including IBD, PSC and PBC, genetic
factors in complex diseases should be considered as "risk-
factor genes" rather than genes responsible for the devel-
opment of a particular disease. Their presence is not syn-
onymous with the development of the disease. Thus,
functional studies should be initiated in order to clarify
the contribution of genetic background in development of
these diseases.
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